Serum Untargeted Metabolomics Reveal Potential Biomarkers of Progression of Diabetic Retinopathy in Asians

Purpose: To reveal molecular mechanisms of diabetic retinopathy (DR) in Asians and facilitate the identification of new therapeutic targets through untargeted metabolomics. To determine the differences in serum metabolites and metabolic pathways between different stages of diabetic retinopathy in pa...

Full description

Bibliographic Details
Main Authors: Zongyi Wang, Jiyang Tang, Enzhong Jin, Yusheng Zhong, Linqi Zhang, Xinyao Han, Jia Liu, Yong Cheng, Jing Hou, Xuan Shi, Huijun Qi, Tong Qian, Li Yuan, Xianru Hou, Hong Yin, Jianhong Liang, Mingwei Zhao, Lvzhen Huang, Jinfeng Qu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Molecular Biosciences
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fmolb.2022.871291/full
_version_ 1818209782578806784
author Zongyi Wang
Jiyang Tang
Enzhong Jin
Yusheng Zhong
Linqi Zhang
Xinyao Han
Jia Liu
Yong Cheng
Jing Hou
Xuan Shi
Huijun Qi
Tong Qian
Li Yuan
Xianru Hou
Hong Yin
Jianhong Liang
Mingwei Zhao
Lvzhen Huang
Jinfeng Qu
author_facet Zongyi Wang
Jiyang Tang
Enzhong Jin
Yusheng Zhong
Linqi Zhang
Xinyao Han
Jia Liu
Yong Cheng
Jing Hou
Xuan Shi
Huijun Qi
Tong Qian
Li Yuan
Xianru Hou
Hong Yin
Jianhong Liang
Mingwei Zhao
Lvzhen Huang
Jinfeng Qu
author_sort Zongyi Wang
collection DOAJ
description Purpose: To reveal molecular mechanisms of diabetic retinopathy (DR) in Asians and facilitate the identification of new therapeutic targets through untargeted metabolomics. To determine the differences in serum metabolites and metabolic pathways between different stages of diabetic retinopathy in patients with type 2 diabetic mellitus (T2DM) and proliferative DR (PDR) and non-proliferative DR (NPDR) and identify differential metabolites between T2DM and DR (NPDR and PDR) patients.Methods: This prospective observational registration study described the differential metabolites between 45 T2DM patients and 15 control cases with no significant differences in clinical characteristics. Their biospecimens and clinical information were collected and recorded in their medical reports. DR phenotypes of the subjects were verified by retina specialists. Serum metabolites were analyzed using high-resolution mass spectrometry with liquid chromatography. Untargeted metabolomics was performed on serum samples from 15 T2DM patients, 15 non-proliferative diabetic retinopathy patients, 15 proliferative diabetic retinopathy patients, and 15 diabetic controls. Discriminatory metabolic features were identified through partial least squares discriminant analysis (PLS-DA), hierarchical clustering analysis (HCA), and generalized linear regression models.Result: Through untargeted metabolomics, 931 features (523 in positive and 408 in negative modes) with 102 common metabolites highly relevant to the presence of DR were detected. In the adjusted analysis, 67 metabolic features differed significantly between T2DM and NPDR patients. Pathway analysis revealed alterations in metabolisms of amino acids and fatty acids. Glutamate, phosphatidylcholine, and 13-hydroperoxyoctadeca-9,11-dienoic acid (13-PHODE) were key contributors to these pathway differences. A total of 171 features distinguished PDR patients from T2DM patients, and pathway analysis revealed alterations in amino acid metabolism, fatty acid metabolism, nitrogen metabolism, and tricarboxylic acid cycle. Aspartate, glutamate, glutamine, ornithine, N-acetyl-l-glutamate, N-acetyl-l-aspartate, citrate, succinate, N-(L-arginino)succinate, 2-oxoglutarate, 13-hydroperoxyoctadeca-9,11-dienoic acid, methionine, lysine, threonine, phenylalanine, N(pi)-methyl-l-histidine, phosphatidylcholine, and linoleate were major contributors to the pathway differences. Between NPDR patients and PDR patients, there were 79 significant differential metabolites. Enrichment pathway analysis showed changes in amino acid metabolism, fatty acid metabolism, pantothenate, and CoA biosynthesis. Aspartate, glutamine, N-acetyl-l-glutamate, N-acetyl-l-aspartate, pantothenate, dihomo-gamma-linolenate, docosahexaenoic acid, and icosapentaenoic acid were key factors for the differences of these pathways.Conclusion: This study demonstrated that the pathways of arginine biosynthesis metabolism, linoleic acid metabolism, alanine, aspartate, and glutamate metabolism, as well as d-glutamine and d-glutamate metabolism, were dysregulated in DR patients of the Asian population. Increased levels of glutamate, aspartate, glutamine, N-acetyl-l-glutamate, and N-acetyl-l-aspartate and decreased levels of dihomo-gamma-linolenate, docosahexaenoic, and icosapentaenoic were considered as the metabolic profile that could distinguish PDR from NPDR in Asians. Phosphatidylcholine and 13-PHODE were identified as two major novel metabolite markers in advanced stages of DR in our study.
first_indexed 2024-12-12T05:06:11Z
format Article
id doaj.art-1286ed664e6a47b8938bb92490664ced
institution Directory Open Access Journal
issn 2296-889X
language English
last_indexed 2024-12-12T05:06:11Z
publishDate 2022-06-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Molecular Biosciences
spelling doaj.art-1286ed664e6a47b8938bb92490664ced2022-12-22T00:37:06ZengFrontiers Media S.A.Frontiers in Molecular Biosciences2296-889X2022-06-01910.3389/fmolb.2022.871291871291Serum Untargeted Metabolomics Reveal Potential Biomarkers of Progression of Diabetic Retinopathy in AsiansZongyi WangJiyang TangEnzhong JinYusheng ZhongLinqi ZhangXinyao HanJia LiuYong ChengJing HouXuan ShiHuijun QiTong QianLi YuanXianru HouHong YinJianhong LiangMingwei ZhaoLvzhen HuangJinfeng QuPurpose: To reveal molecular mechanisms of diabetic retinopathy (DR) in Asians and facilitate the identification of new therapeutic targets through untargeted metabolomics. To determine the differences in serum metabolites and metabolic pathways between different stages of diabetic retinopathy in patients with type 2 diabetic mellitus (T2DM) and proliferative DR (PDR) and non-proliferative DR (NPDR) and identify differential metabolites between T2DM and DR (NPDR and PDR) patients.Methods: This prospective observational registration study described the differential metabolites between 45 T2DM patients and 15 control cases with no significant differences in clinical characteristics. Their biospecimens and clinical information were collected and recorded in their medical reports. DR phenotypes of the subjects were verified by retina specialists. Serum metabolites were analyzed using high-resolution mass spectrometry with liquid chromatography. Untargeted metabolomics was performed on serum samples from 15 T2DM patients, 15 non-proliferative diabetic retinopathy patients, 15 proliferative diabetic retinopathy patients, and 15 diabetic controls. Discriminatory metabolic features were identified through partial least squares discriminant analysis (PLS-DA), hierarchical clustering analysis (HCA), and generalized linear regression models.Result: Through untargeted metabolomics, 931 features (523 in positive and 408 in negative modes) with 102 common metabolites highly relevant to the presence of DR were detected. In the adjusted analysis, 67 metabolic features differed significantly between T2DM and NPDR patients. Pathway analysis revealed alterations in metabolisms of amino acids and fatty acids. Glutamate, phosphatidylcholine, and 13-hydroperoxyoctadeca-9,11-dienoic acid (13-PHODE) were key contributors to these pathway differences. A total of 171 features distinguished PDR patients from T2DM patients, and pathway analysis revealed alterations in amino acid metabolism, fatty acid metabolism, nitrogen metabolism, and tricarboxylic acid cycle. Aspartate, glutamate, glutamine, ornithine, N-acetyl-l-glutamate, N-acetyl-l-aspartate, citrate, succinate, N-(L-arginino)succinate, 2-oxoglutarate, 13-hydroperoxyoctadeca-9,11-dienoic acid, methionine, lysine, threonine, phenylalanine, N(pi)-methyl-l-histidine, phosphatidylcholine, and linoleate were major contributors to the pathway differences. Between NPDR patients and PDR patients, there were 79 significant differential metabolites. Enrichment pathway analysis showed changes in amino acid metabolism, fatty acid metabolism, pantothenate, and CoA biosynthesis. Aspartate, glutamine, N-acetyl-l-glutamate, N-acetyl-l-aspartate, pantothenate, dihomo-gamma-linolenate, docosahexaenoic acid, and icosapentaenoic acid were key factors for the differences of these pathways.Conclusion: This study demonstrated that the pathways of arginine biosynthesis metabolism, linoleic acid metabolism, alanine, aspartate, and glutamate metabolism, as well as d-glutamine and d-glutamate metabolism, were dysregulated in DR patients of the Asian population. Increased levels of glutamate, aspartate, glutamine, N-acetyl-l-glutamate, and N-acetyl-l-aspartate and decreased levels of dihomo-gamma-linolenate, docosahexaenoic, and icosapentaenoic were considered as the metabolic profile that could distinguish PDR from NPDR in Asians. Phosphatidylcholine and 13-PHODE were identified as two major novel metabolite markers in advanced stages of DR in our study.https://www.frontiersin.org/articles/10.3389/fmolb.2022.871291/fullType 2 diabetesproliferative diabetic retinopathynon-proliferative diabetic retinopathymetabolomicsuntargeted metabolomicsmetabolic profiling
spellingShingle Zongyi Wang
Jiyang Tang
Enzhong Jin
Yusheng Zhong
Linqi Zhang
Xinyao Han
Jia Liu
Yong Cheng
Jing Hou
Xuan Shi
Huijun Qi
Tong Qian
Li Yuan
Xianru Hou
Hong Yin
Jianhong Liang
Mingwei Zhao
Lvzhen Huang
Jinfeng Qu
Serum Untargeted Metabolomics Reveal Potential Biomarkers of Progression of Diabetic Retinopathy in Asians
Frontiers in Molecular Biosciences
Type 2 diabetes
proliferative diabetic retinopathy
non-proliferative diabetic retinopathy
metabolomics
untargeted metabolomics
metabolic profiling
title Serum Untargeted Metabolomics Reveal Potential Biomarkers of Progression of Diabetic Retinopathy in Asians
title_full Serum Untargeted Metabolomics Reveal Potential Biomarkers of Progression of Diabetic Retinopathy in Asians
title_fullStr Serum Untargeted Metabolomics Reveal Potential Biomarkers of Progression of Diabetic Retinopathy in Asians
title_full_unstemmed Serum Untargeted Metabolomics Reveal Potential Biomarkers of Progression of Diabetic Retinopathy in Asians
title_short Serum Untargeted Metabolomics Reveal Potential Biomarkers of Progression of Diabetic Retinopathy in Asians
title_sort serum untargeted metabolomics reveal potential biomarkers of progression of diabetic retinopathy in asians
topic Type 2 diabetes
proliferative diabetic retinopathy
non-proliferative diabetic retinopathy
metabolomics
untargeted metabolomics
metabolic profiling
url https://www.frontiersin.org/articles/10.3389/fmolb.2022.871291/full
work_keys_str_mv AT zongyiwang serumuntargetedmetabolomicsrevealpotentialbiomarkersofprogressionofdiabeticretinopathyinasians
AT jiyangtang serumuntargetedmetabolomicsrevealpotentialbiomarkersofprogressionofdiabeticretinopathyinasians
AT enzhongjin serumuntargetedmetabolomicsrevealpotentialbiomarkersofprogressionofdiabeticretinopathyinasians
AT yushengzhong serumuntargetedmetabolomicsrevealpotentialbiomarkersofprogressionofdiabeticretinopathyinasians
AT linqizhang serumuntargetedmetabolomicsrevealpotentialbiomarkersofprogressionofdiabeticretinopathyinasians
AT xinyaohan serumuntargetedmetabolomicsrevealpotentialbiomarkersofprogressionofdiabeticretinopathyinasians
AT jialiu serumuntargetedmetabolomicsrevealpotentialbiomarkersofprogressionofdiabeticretinopathyinasians
AT yongcheng serumuntargetedmetabolomicsrevealpotentialbiomarkersofprogressionofdiabeticretinopathyinasians
AT jinghou serumuntargetedmetabolomicsrevealpotentialbiomarkersofprogressionofdiabeticretinopathyinasians
AT xuanshi serumuntargetedmetabolomicsrevealpotentialbiomarkersofprogressionofdiabeticretinopathyinasians
AT huijunqi serumuntargetedmetabolomicsrevealpotentialbiomarkersofprogressionofdiabeticretinopathyinasians
AT tongqian serumuntargetedmetabolomicsrevealpotentialbiomarkersofprogressionofdiabeticretinopathyinasians
AT liyuan serumuntargetedmetabolomicsrevealpotentialbiomarkersofprogressionofdiabeticretinopathyinasians
AT xianruhou serumuntargetedmetabolomicsrevealpotentialbiomarkersofprogressionofdiabeticretinopathyinasians
AT hongyin serumuntargetedmetabolomicsrevealpotentialbiomarkersofprogressionofdiabeticretinopathyinasians
AT jianhongliang serumuntargetedmetabolomicsrevealpotentialbiomarkersofprogressionofdiabeticretinopathyinasians
AT mingweizhao serumuntargetedmetabolomicsrevealpotentialbiomarkersofprogressionofdiabeticretinopathyinasians
AT lvzhenhuang serumuntargetedmetabolomicsrevealpotentialbiomarkersofprogressionofdiabeticretinopathyinasians
AT jinfengqu serumuntargetedmetabolomicsrevealpotentialbiomarkersofprogressionofdiabeticretinopathyinasians